This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
DE Adson , MG Kushner , KM Eiben , SC Schulz (2004). Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depression and Anxiety 19, 121–126.
C Allgulander , AA Dahl , C Austin , PL Morris , (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. American Journal of Psychiatry 161, 1642–1649.
LA Arvanitis , BG Miller , the Seroquel Trial 13 Study Group (1997). Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 42, 233–246.
SG Ball , A Kuhn , D Wall , A Shekhar , (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry 66, 94–99.
B Bandelow , J Zohar , E Hollander , S Kasper , (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders – First Revision. World Journal of Biological Psychiatry 9, 248–312.
M Bauer , HW Pretorius , EL Constant , WR Earley , (2009). Extended release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry 70, 540–549.
DJ Buysse , CF Reynolds III, TH Monk , SR Berman , (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research 28, 193–213.
JR Calabrese , PE Keck Jr., W Macfadden , M Minkwitz , (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 1351–1360.
AJ Cutler , SA Montgomery , D Feifel , A Lazarus , (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Journal of Clinical Psychiatry 70, 526–539.
GA Fava , M Bernardi , E Tomba , C Rafanelli (2007). Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. International Journal of Neuropsychopharmacology 10, 835–838.
I Galynker , A Khan , Y Grebchenko , A Ten , (2005). Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. Journal of Clinical Psychiatry 66, 544.
S Ganesan , V Agambaram , F Randeree , I Eggens , (2008). Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Current Medical Research and Opinion 24, 21–32.
AJ Gelenberg , RB Lydiard , RL Rudolph , L Aguiar , (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 283, 3082–3088.
JM Goldstein , S Nyberg , M Brecher (2008). Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. European Psychiatry 23 (Suppl. 2), S202.
NH Jensen , RM Rodriguiz , MG Caron , WC Wetsel , (2008). N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 2303–2312.
LL Judd , RC Kessler , MP Paulus , PV Zeller , (1998). Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatrica Scandinavica (Suppl. 393), 6–11.
RS Kahn , SC Schulz , VD Palazov , EB Reyes , (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 68, 832–842.
MA Katzman , M Vermani , L Jacobs , M Marcus , (2008 b). Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. Journal of Anxiety Disorders 22, 1480–1486.
A Keller , EL McGarvey , AH Clayton (2006). Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). Journal of Sex and Marital Therapy 32, 43–52.
A Kott , D Cicchetti , O Markovic , C Spear (2008). Assessing the ability of rater training to achieve good-to-excellent inter-rater reliability on the HAM-A using kappa statistics. European Psychiatry 23, S214.
RJ Leo (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57, 449–454.
C Maciag , J Smolka , J McLaughlin , T Hudzik , (2007). Anxiolytic effects of quetiapine in rat punished responding: mechanism of action and the role of D2 antagonism. European Neuropsychopharmacology 17 (Suppl. 4), S399.
DM Marks , MH Park , BJ Ham , C Han , (2008). Paroxetine: safety and tolerability issues. Expert Opinion on Drug Safety 7, 783–794.
D Michelson , M Fava , J Amsterdam , J Apter , (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry 176, 363–368.
SA Montgomery (2006). Pregabalin for the treatment of generalised anxiety disorder. Expert Opinion on Pharmacotherapy 7, 2139–2154.
D Nutt , S Argyropoulos , S Hood , J Potokar (2006). Generalized anxiety disorder: a comorbid disease. European Neuropsychopharmacology 16 (Suppl. 2), S109–S118.
GN Papadimitriou , P Linkowski (2005). Sleep disturbance in anxiety disorders. International Review of Psychiatry 17, 229–236.
MH Pollack , R Zaninelli , A Goddard , JP McCafferty , (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350–357.
K Rickels , MH Pollack , DE Feltner , RB Lydiard , (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 1022–1030.
K Rickels , CC Weise , H Feldman , EA Fee , (1978). Loxapine in neurotic anxiety: some modifiers of treatment response. Journal of International Medical Research 6, 180–185.
K Rickels , R Zaninelli , J McCafferty , K Bellew , (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749–756.
G Rubio , JJ Lopez-Ibor (2007). Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatrica Scandinavica 115, 372–379.
NM Simon , KM Connor , RT Lebeau , EA Hoge , (2008). Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berlin) 197, 675–681.
ME Thase , W Macfadden , RH Weisler , W Chang , (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology 26, 600–609.
K Timdahl , A Carlsson , G Stening (2007). An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Human Psychopharmacology 22, 315–325.
P Tyrer , D Baldwin (2006). Generalised anxiety disorder. Lancet 368, 2156–2166.
J Yamamoto , FM Kline , RW Burgoyne (1973). The treatment of severe anxiety in outpatients: a controlled study comparing chlordiazepoxide and chlorpromazine. Psychosomatics 14, 46–51.
KA Yonkers , IR Dyck , M Warshaw , MB Keller (2000). Factors predicting the clinical course of generalised anxiety disorder. British Journal of Psychiatry 176, 544–549.